<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106701</url>
  </required_header>
  <id_info>
    <org_study_id>IRCCSDonato</org_study_id>
    <nct_id>NCT03106701</nct_id>
  </id_info>
  <brief_title>Epicardial Ablation in Brugada Syndrome. An Extension Study of 200 BrS.Patients</brief_title>
  <official_title>Epicardial Ablation in 200 Consecutive Brugada Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Donato</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study represents an extension of a previous study (NCT02641431) on the acute and
      long-term benefit of epicardial ablation on elimination of both BrS-ECG pattern and VT/VF
      inducibility in 200 consecutive BrS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to previous protocol (NCT02641431), additional consecutive selected patients
      having an ICD implantation will be enrolled up to a total of 200 BrS patients.
      Three-dimensional color-coded voltage, activation and duration electroanatomical maps before
      and after ajmaline (1mg/kg in 5 minutes) wiil determine the site and the size of the
      arrhythmogenic substrate as characterized by abnormally prolonged fragmented ventricular
      potentials. Primary endpoint will be identification and elimination of this
      electrophysiological substrate by RF applications leading to ECG pattern normalization and
      VT/VF non-inducibility before and after ajmaline. Patients will be followed up to 48 months
      after ablation by sequential 12-lead ECG and Holter recording, ICD interrogation, VT/VF
      inducibility before and after ajmaline test.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Anticipated">March 14, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type 1 BrS-ECG pattern elimination by epicardial ablation before and after ajmaline test.</measure>
    <time_frame>1 day after ablation</time_frame>
    <description>Normalization of ECG pattern after elimination by radio-frequency ablation of all abnormal epicardial potentials</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>3 months</time_frame>
    <description>Abolition of all abnormal epicardial electrograms before and after ajmaline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes at EP study</measure>
    <time_frame>3 months</time_frame>
    <description>Non-inducibility of VT/VT at programmed electrophysiological study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>6 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes</measure>
    <time_frame>6 months</time_frame>
    <description>ICD interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes</measure>
    <time_frame>12 months</time_frame>
    <description>ICD interrogation and ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>12 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>18 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes</measure>
    <time_frame>24 months</time_frame>
    <description>ICD interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br ECG pattern after ajmaline test</measure>
    <time_frame>24 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes at EP study</measure>
    <time_frame>36 months</time_frame>
    <description>ICD interrogation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>36 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of Br Pattern at ajmaline test</measure>
    <time_frame>48 months</time_frame>
    <description>Normalization of 12-lead ECG recording at baseline and after ajmaline test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absence of VA episodes at EP study</measure>
    <time_frame>48 months</time_frame>
    <description>ICD interrogation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>ECG Brugada Pattern (Elimination)</condition>
  <arm_group>
    <arm_group_label>Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency epicardial ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Epicardial Radiofrequency ablation</description>
    <arm_group_label>Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic BrS patients, ICD implantation, spontaneous or ajmaline-induced type 1 Br
             pattern.

        Exclusion Criteria:

          -  Age &lt; 18 years, prior epicardial ablation, pregnancy, co-morbidities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Pappone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico San Donato, Milan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRCCS Policlinico S. Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>Milano</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 4, 2017</lastchanged_date>
  <firstreceived_date>March 14, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Donato</investigator_affiliation>
    <investigator_full_name>Carlo Pappone</investigator_full_name>
    <investigator_title>Department Director, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Brugada Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
